melatonin has been researched along with Central Nervous System Diseases in 15 studies
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
Excerpt | Relevance | Reference |
---|---|---|
"Melatonin is an important neuroprotective factor and its receptors are expressed in the fetal brain." | 6.53 | Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders. ( Assunção Salustiano, EM; Sagrillo-Fagundes, L; Soliman, A; Vaillancourt, C; Yen, PW, 2016) |
"Melatonin was associated with earlier waking times than placebo (29." | 2.77 | Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. ( Allport, T; Appleton, R; Choonara, I; Edmond, A; Gamble, C; Gringras, P; Jones, AP; Montgomery, P; Sutcliffe, A; Whitehouse, WP; Wiggs, L; Williamson, PR, 2012) |
"Melatonin is a hormone produced in and secreted by the pineal gland." | 2.72 | The Effect of Melatonin Modulation of Non-coding RNAs on Central Nervous System Disorders: An Updated Review. ( Chen, S; Fang, Y; Lu, J; Luo, Y; Mei, S; Zhang, J, 2021) |
"Melatonin is an important hormone regulating circadian rhythm, neuroprotection and neuroimmune processes." | 2.61 | The evolutionarily conserved role of melatonin in CNS disorders and behavioral regulation: Translational lessons from zebrafish. ( Amstislavskaya, TG; Bashirzade, A; de Abreu, MS; Demin, KA; Dos Santos, BE; Genario, R; Giacomini, ACVV; Kalueff, AV; Marchiori, NI; Volgin, AD, 2019) |
"Melatonin is an important neuroprotective factor and its receptors are expressed in the fetal brain." | 2.53 | Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders. ( Assunção Salustiano, EM; Sagrillo-Fagundes, L; Soliman, A; Vaillancourt, C; Yen, PW, 2016) |
" The optimal dosage and timing of drug administration is still unclear." | 2.40 | Melatonin: therapeutic use in sleep disorders. ( Chase, JE; Gidal, BE, 1997) |
"Melatonin was recently reported to be an effective free radical scavenger and antioxidant." | 2.40 | Oxidative damage in the central nervous system: protection by melatonin. ( Reiter, RJ, 1998) |
"In primary or no-comorbid insomnia, only a 2 mg dose of slow release MEL, 1 to 2 hours before bedtime, over a period of 3 to 12 weeks, is recommended." | 1.62 | Melatonin (MEL) and its use in neurological diseases and insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS). ( Kilic-Huck, U; Quera-Salva, MA; Vecchierini, MF, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (13.33) | 18.2507 |
2000's | 3 (20.00) | 29.6817 |
2010's | 8 (53.33) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
Authors | Studies |
---|---|
Lu, J | 1 |
Luo, Y | 1 |
Mei, S | 1 |
Fang, Y | 1 |
Zhang, J | 1 |
Chen, S | 1 |
Vecchierini, MF | 1 |
Kilic-Huck, U | 1 |
Quera-Salva, MA | 1 |
Tamtaji, OR | 1 |
Mirhosseini, N | 1 |
Reiter, RJ | 3 |
Azami, A | 1 |
Asemi, Z | 1 |
Genario, R | 1 |
Giacomini, ACVV | 1 |
Demin, KA | 1 |
Dos Santos, BE | 1 |
Marchiori, NI | 1 |
Volgin, AD | 1 |
Bashirzade, A | 1 |
Amstislavskaya, TG | 1 |
de Abreu, MS | 1 |
Kalueff, AV | 1 |
Sagrillo-Fagundes, L | 1 |
Assunção Salustiano, EM | 1 |
Yen, PW | 1 |
Soliman, A | 1 |
Vaillancourt, C | 1 |
Anderson, G | 1 |
Yu, X | 1 |
Li, Z | 1 |
Zheng, H | 1 |
Ho, J | 1 |
Chan, MT | 1 |
Wu, WK | 1 |
Eynan, M | 1 |
Biram, A | 1 |
Mullokandov, M | 1 |
Kronfeld-Schor, N | 1 |
Paz-Cohen, R | 1 |
Menajem, D | 1 |
Arieli, Y | 1 |
Guven, A | 1 |
Yavuz, O | 1 |
Cam, M | 1 |
Comunoglu, C | 1 |
Sevi'nc, O | 1 |
Lerchl, A | 1 |
Gringras, P | 1 |
Gamble, C | 1 |
Jones, AP | 1 |
Wiggs, L | 1 |
Williamson, PR | 1 |
Sutcliffe, A | 1 |
Montgomery, P | 1 |
Whitehouse, WP | 1 |
Choonara, I | 1 |
Allport, T | 1 |
Edmond, A | 1 |
Appleton, R | 1 |
Bruguerolle, B | 1 |
Chase, JE | 1 |
Gidal, BE | 1 |
Arushanian, EB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
9 reviews available for melatonin and Central Nervous System Diseases
Article | Year |
---|---|
The Effect of Melatonin Modulation of Non-coding RNAs on Central Nervous System Disorders: An Updated Review.
Topics: Central Nervous System Diseases; Humans; Melatonin; MicroRNAs; RNA, Long Noncoding; RNA, Untranslate | 2021 |
Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives.
Topics: Animals; Calpain; Central Nervous System; Central Nervous System Diseases; Cysteine Proteinase Inhib | 2019 |
The evolutionarily conserved role of melatonin in CNS disorders and behavioral regulation: Translational lessons from zebrafish.
Topics: Animals; Behavior, Animal; Brain; Central Nervous System Diseases; Disease Models, Animal; Humans; M | 2019 |
Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders.
Topics: Antioxidants; Brain; Central Nervous System Diseases; Female; Fetus; Humans; Melatonin; Neuroprotect | 2016 |
Protective roles of melatonin in central nervous system diseases by regulation of neural stem cells.
Topics: Animals; Cell Differentiation; Central Nervous System Diseases; Humans; Melatonin; Neural Stem Cells | 2017 |
[Interactions of melatonin with the central nervous system].
Topics: Central Nervous System; Central Nervous System Diseases; Circadian Rhythm; Humans; Melatonin; Neurot | 2006 |
Melatonin: therapeutic use in sleep disorders.
Topics: Adult; Aged; Central Nervous System Diseases; Circadian Rhythm; Female; Humans; Male; Melatonin; Mid | 1997 |
Oxidative damage in the central nervous system: protection by melatonin.
Topics: Animals; Antioxidants; Central Nervous System Diseases; Disease Models, Animal; Free Radical Scaveng | 1998 |
[Brain rhythm-organizing structures and pharmacological effect].
Topics: Animals; Antidepressive Agents; Central Nervous System Diseases; Circadian Rhythm; Emotions; Humans; | 2000 |
1 trial available for melatonin and Central Nervous System Diseases
Article | Year |
---|---|
Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial.
Topics: Adolescent; Central Nervous System Depressants; Central Nervous System Diseases; Child; Child Behavi | 2012 |
5 other studies available for melatonin and Central Nervous System Diseases
Article | Year |
---|---|
Melatonin (MEL) and its use in neurological diseases and insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS).
Topics: Central Nervous System Diseases; Circadian Rhythm; Humans; Melatonin; Quality of Life; Sleep; Sleep | 2021 |
Editorial: The Kynurenine and Melatonergic Pathways in Psychiatric and CNS Disorders.
Topics: Central Nervous System Diseases; Humans; Kynurenine; Melatonin; Mental Disorders; Signal Transductio | 2016 |
The transition from day-to-night activity is a risk factor for the development of CNS oxygen toxicity in the diurnal fat sand rat (Psammomys obesus).
Topics: Animals; Antioxidants; Biological Clocks; Central Nervous System Diseases; Circadian Rhythm; Gerbill | 2017 |
Central nervous system complications of diabetes in streptozotocin-induced diabetic rats: a histopathological and immunohistochemical examination.
Topics: Animals; Antioxidants; Brain Chemistry; Central Nervous System Diseases; Cerebellum; Cerebral Cortex | 2009 |
Treatment of sleep disorders with melatonin.
Topics: Central Nervous System Diseases; Developmental Disabilities; Female; Humans; Male; Melatonin; Sleep; | 2012 |